Meghan Sharp is listed as a director on 8 SEC Form D filings by 2 issuers between May 2013 and May 2017: CHROMATIN, INC. (Chicago, IL — industry reported as "Other" — 2013–2017; $23.6M reported sold to 18 investors) and BIOSYNTHETIC TECHNOLOGIES, LLC (Irvine, CA — manufacturing — 2013–2017; $16.5M reported sold to 13 investors).
What this means 2 separate companies raised money with this person listed as director, over about 4 years. Across those companies the filings report $40.1M sold in total.
Listed alongside Allen Barbieri (5 shared filings), Gerald Kohlenberger (5 shared filings), John Hopkins (5 shared filings), Kent Wasson (5 shared filings), Bernhard Mohr (3 shared filings) and 18 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Meghan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 8 public filings for Meghan Sharp and found 6 differences, 2 worth asking the sponsor about: Form D filed 136 days after the first sale; Form D filed 234 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.